This site is intended for health professionals only

Wednesday 19 June 2019
LatestNews
Share |

Latest News

Lynparza approved for first-line maintenance treatment of BRCA-mutated advanced ovarian cancer

Tuesday 18th June 2019
AstraZeneca and MSD have announced that the European Commission (EC) has approved Lynparza (olaparib) as a 1st-line maintenance treatment for women with BRCA-mutated advanced ovarian cancer.
 
The licensed indication is as a maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (...
Thu, 13 Jun 2019
ApoB:A1 ratio and metabolomic lipoprotein signatures identified as new biomarkers for cardiovascular risk in juvenile SLE patients
Thu, 13 Jun 2019
Study includes data from over 8000 people with psoriatic arthritis from four Nordic countries
Thu, 13 Jun 2019
A collaboration between hospitals and pharmacies in Cheshire and Merseyside has saved the NHS £11 million – and improved patient care
Wed, 12 Jun 2019
Decision based on data from Phase III head-to-head study stopped early due to an overall survival efficacy benefit versus sunitinib, a current standard of care
Wed, 12 Jun 2019
Cardiovascular health and physical activity levels of prostate cancer patients improve following successful interventions by community pharmacies, new research in the British Medical Journal reports
Mon, 10 Jun 2019
An upsurge in demand for proton beam therapy was predicted as the centenary of the discovery of the proton was celebrated at a major scientific conference
Mon, 10 Jun 2019
Oral semaglutide is an investigational once-daily oral glucagon-like peptide-1 receptor agonist